L1CA34 Overzicht aandelen Labcorp Holdings Inc. biedt laboratoriumdiensten aan. Meer informatie
Beloningen Risicoanalyse Alle risicocontroles bekijken Leg je gedachten, links en bedrijfsverhaal vast
Labcorp Holdings Inc. Concurrenten Prijsgeschiedenis en prestaties
Overzicht van hoogtepunten, dieptepunten en veranderingen in de aandelenkoersen voor Labcorp Holdings Historische aandelenkoersen Huidige aandelenkoers US$357.60 52 Week Hoogtepunt US$359.71 52 Week Laag US$250.00 Bèta 1.05 1 maand verandering n/a 3 maanden verandering n/a 1 Jaar Verandering 29.47% 3 jaar verandering -0.96% 5 jaar verandering 77.12% Verandering sinds IPO 90.82%
Recent nieuws en updates Labcorp Holdings Inc. Declares Quarterly Cash Dividend, Payable on March 12, 2025
Labcorp Launches H5 Bird Flu Test in the U.S., Now Available for Order Through Physicians Dec 18
Labcorp Holdings Inc. (NYSE:LH) completed the acquisition of Select Outreach Services of Ballad Health. Dec 13 Labcorp Holdings Inc. Announces Chief Financial Officer Changes
Labcorp Holdings Inc. Updates Earnings Guidance for the Year 2024 Oct 24 Labcorp Expands Sexually Transmitted Infection Test Offerings with Rapid Syphilis Test Meer updates bekijken Labcorp Holdings Inc. Declares Quarterly Cash Dividend, Payable on March 12, 2025
Labcorp Launches H5 Bird Flu Test in the U.S., Now Available for Order Through Physicians Dec 18
Labcorp Holdings Inc. (NYSE:LH) completed the acquisition of Select Outreach Services of Ballad Health. Dec 13 Labcorp Holdings Inc. Announces Chief Financial Officer Changes
Labcorp Holdings Inc. Updates Earnings Guidance for the Year 2024 Oct 24 Labcorp Expands Sexually Transmitted Infection Test Offerings with Rapid Syphilis Test
Labcorp Holdings Inc. to Report Q3, 2024 Results on Oct 24, 2024 Sep 25
Labcorp Holdings Inc. (NYSE:LH) agreed to acquire 15% stake in SYNLAB AG (HMSE:SYAB) from Cinven Limited for €140 million. Sep 19
Laboratory Corporation of America Holdings (NYSE:LH) completed the acquisition of an Asset Purchase Agreement to acquire Select Assets of BioReference Health, LLC for approximately $240 million. Sep 17
Laboratory Corporation of America Holdings (NYSE:LH) completed the acquisition of Substantially all Assets of Invitae Corporation (OTCPK:NVTA.Q). Aug 07
Labcorp Holdings Inc. Receives FDA De Novo Marketing Authorization for Pgdx Elio™ Plasma Focus Dx Aug 02
Labcorp Holdings Inc. Revises Financial Guidance for the Full Year 2024 Aug 01
Labcorp Declares Quarterly Cash Dividend, Payable on September 13, 2024 Jul 25
Labcorp Holdings Inc. to Report Q2, 2024 Results on Aug 01, 2024 Jul 02
Labcorp Launches Labcorp Global Trial Connect to Accelerate Clinical Trials Jun 18
Labcorp Holdings Inc. Announces New Strategic Service Offerings Within Precision Oncology Portfolio Jun 05
Labcorp Introduces First Trimester Screening Test to Assess Preeclampsia Risk During Pregnancy May 16
Labcorp Receives FDA Approval for First Companion Diagnostic for Use with Pfizer's Newly Approved Gene Therapy to Treat Patients with Hemophilia B Apr 30
Laboratory Corporation of America Holdings (NYSE:LH) agreed to acquire Substantially all Assets of Invitae Corporation for approximately $240 million. Apr 26
Labcorp Announces First-of-Its-Kind Test for Early Indication of Neurodegenerative Diseases and Brain Injuries Using a Blood Draw Apr 15 Labcorp Declares Quarterly Dividend, Payable on June 12, 2024
Labcorp Announces Expansion of Precision Oncology Portfolio to Support Pharmaceutical, Biopharma, and Clinical Research in Advancing Drug Development Programs Apr 10 Laboratory Corporation of America Holdings, Annual General Meeting, May 14, 2024
Labcorp to Present Diverse Portfolio of Precision Oncology Research at the Annual Meeting of the American Association for Cancer Research Apr 02
Laboratory Corporation of America Holdings to Report Q1, 2024 Results on Apr 25, 2024 Mar 29
Laboratory Corporation of America Holdings to Report Q1, 2024 Results on Apr 25, 2024 Mar 28
Labcorp Launches pTau217 Blood Biomarker Test to Accelerate Path to Diagnosis of Alzheimer's Disease and Support Clinical Trials Mar 20
Labcorp Launches Weight Loss Management Testing Solutions Mar 07
Laboratory Corporation of America Holdings Announces Quarterly Cash Dividend, Payable on March 13, 2024 Feb 16
Labcorp Announces the Launch and Availability of A New, FDA-Cleared Blood Test for Risk Assessment and Clinical Management of Severe Preeclampsia Jan 31
Laboratory Corporation of America Holdings to Report Q4, 2023 Results on Feb 15, 2024 Jan 17
Labcorp Declares Quarterly Cash Dividend, Payable on March 13, 2024 Jan 12
Laboratory Corporation of America Holdings (NYSE:LH) completed the acquisition of Outreach laboratory business from Legacy Health System Insurance Company. Nov 21
Geneoscopy, Inc. Signs Multi-Year Agreement with Labcorp to Distribute Noninvasive Multi-Target Stool Rna (Mt-Srna) Colorectal Cancer Screening Test Nov 15
Labcorp Declares a Cash Dividend, Payable on December 12, 2023 Oct 13
Laboratory Corporation of America Holdings (NYSE:LH) agreed to acquire Outreach Laboratory Business of Baystate Health, Inc. Oct 06
Laboratory Corporation of America Holdings to Report Q3, 2023 Results on Oct 26, 2023 Sep 30
Laboratory Corporation of America Holdings (NYSE:LH) entered into an agreement to acquire Outreach Laboratory Business and Select Operating Assets from Tufts Medicine, Inc. Aug 04
Laboratory Corporation of America Holdings Announces Quarterly Cash Dividend, Payable on September 8, 2023 Jul 28 Laboratory Corporation of America Holdings acquired Clinical Laboratory Division from Enzo Biochem, Inc. for approximately $115 million. Jul 25
Laboratory Corporation of America Holdings (NYSE:LH) completed the acquisition of Outreach laboratory services assets of Jefferson Health. Jul 14
Laboratory Corporation of America Holdings (NYSE:LH) entered into an agreement to acquire Outreach laboratory business from Legacy Health System Insurance Company. Jul 12
Laboratory Corporation of America Holdings to Report Q2, 2023 Results on Jul 27, 2023 Jun 30
Laboratory Corporation of America Holdings Appoints Paul B. Rothman as a Member of the Board Jun 08
Laboratory Corporation of America Holdings Launches Labcorp Plasma Focus Jun 01
Laboratory Corporation of America Holdings (NYSE:LH) entered into an agreement to acquire the outreach laboratory business and select assets of Providence Health & Services - Oregon. May 17 Laboratory Corporation of America Holdings Appoints Mark S. Schroeder to Executive Vice President, President Diagnostics & Chief Operations Officer
Laboratory Corporation of America Holdings Provides Earnings Guidance for the Year 2023 Feb 17
Laboratory Corporation of America Holdings to Report Q4, 2022 Results on Feb 16, 2023 Jan 19
Labcorp Declares Cash Dividend on Common Stock, Payable on March 13, 2023 Jan 13
Labcorp Announces Executive Changes Jan 06
Laboratory Corporation of America Holdings Appoints Kirsten Kliphouse to Board of Directors Oct 14
Labcorp Declares Quarterly Dividend, Payable on December 9, 2022 Oct 13
Laboratory Corporation of America Holdings (NYSE:LH) acquired Certain Outreach Laboratory Assets from Certain Outreach Laboratory Assets. Oct 04
Laboratory Corporation of America Holdings to Report Q3, 2022 Results on Oct 27, 2022 Sep 28
Laboratory Corporation of America Holdings (NYSE:LH) acquired Clinical Outreach Laboratory Business and Select Related Assets of RWJBarnabas Health. Aug 24
Laboratory Corporation of America Holdings Launches Labcorp Clinical Decision Support (CDS) interpretative test report for its Stinging Insect Component-Specific IgE Test Jul 20 Laboratory Corporation of America Holdings to Report Q2, 2022 Results on Jul 28, 2022
Labcorp to Begin Testing for Monkeypox Using the U.S. Centers for Disease Control and Prevention’s Othopoxvirus Test Jul 07 Labcorp Launches New Test for People with Skin Cancer Laboratory Corporation of America Holdings (NYSE:LH) acquired Select Assets from the Clinical Outreach Business of AtlantiCare. May 10
Labcorp Launches Convenient Home Diagnostic Test Collection Service in Collaboration With Getlabs Apr 23
Labcorp Initiates Quarterly Dividend, Payable on June 9, 2022 Apr 08
Laboratory Corporation of America Holdings, Annual General Meeting, May 11, 2022 Apr 01
Laboratory Corporation of America Holdings to Report Q1, 2022 Results on Apr 28, 2022 Mar 29
Laboratory Corporation of America Holdings (NYSE:LH) completed the acquisition of Personal Genome Diagnostics Inc. Feb 22
Laboratory Corporation of America Holdings Provides Earning Guidance of 2022 Feb 13
Labcorp Launches Labcorp OnDemand Digital Health Platform Feb 05
Laboratory Corporation of America Holdings (NYSE:LH) entered into a definitive agreement to acquire Personal Genome Diagnostics Inc for $580 million. Dec 24
Laboratory Corporation of America Holdings (NYSE:LH) announces an Equity Buyback for $2,500 million worth of its shares. Dec 10
Laboratory Corporation of America Holdings (NYSE:LH) completed the acquisition of Toxikon Corp. Dec 05
Laboratory Corporation of America Holdings (NYSE:LH) completed the acquisition of Autoimmune’s Vectra Testing Business from Myriad Genetics, Inc. (NasdaqGS:MYGN). Sep 14
Laboratory Corporation of America Holdings (NYSE:LH) completed the acquisition of Ovia Health Inc. Aug 14
Labcorp Launches Companion Diagnostic for Amgen’s Newly-Approved Lung Cancer Therapy Jul 03
Laboratory Corporation of America Holdings(NYSE:LH) dropped from Russell 1000 Growth Index Jun 28
Laboratory Corporation of America Holdings(NYSE:LH) dropped from Russell 1000 Dynamic Index Jun 27
Labcorp And OmniSeq Launch INSIGHT, Next-Generation Sequencing Platform to Advance Precision Oncology Jun 15
Labcorp Announces That Pixel by Labcorp COVID-19 PCR Test Home Collection Kits Jun 09
Labcorp to Introduce Combined Oncology Offering At 2021 ASCO® Annual Meeting Jun 03
Labcorp Study Suggests COVID-19 Antibodies Remain At Least 10 Months After Infection May 25
Pixel by Labcorp COVID-19 PCR Test Home Collection Kit Receives FDA Emergency Authorization for Ages 2-17 May 14
Labcorp Revises Earnings Guidance for the Full Year 2021 Apr 30
WELL Health's Circle Medical to Offer Labcorp's At Home COVID-19 Self-Collection Test and Announces Clinical Expansion to Austin and San Diego Markets Mar 11
Adaptive Biotechnologies Expands Collaboration with Labcorp to Increase Access to Growing Research and Clinical Diagnostic Portfolio Feb 24
Labcorp Adds High Sensitivity Antigen Test to Screen for Active COVID-19 Infection Feb 18
Labcorp Announces Management Appointments Feb 10
Laboratory Corporation of America Holdings(NYSE:LH) dropped from Russell 1000 Defensive Index Jan 28
Laboratory Corporation of America Holdings Announces Executive Changes Jan 20
Laboratory Corporation of America Holdings to Report Q4, 2020 Results on Feb 11, 2021 Jan 09 Rendement voor aandeelhouders L1CA34 BR Healthcare BR Markt 7D n/a -0.9% 0.9% 1Y 29.5% -19.2% -7.2%
Bekijk het volledige aandeelhoudersrendement
Rendement versus industrie: L1CA34 overtrof de BR Healthcare industrie, die het afgelopen jaar een rendement -19.2 % opleverde.
Rendement versus markt: L1CA34 overtrof de BR markt, die het afgelopen jaar een rendement opleverde van -7.2 %.
Prijsvolatiliteit Is L1CA34's price volatile compared to industry and market? L1CA34 volatility L1CA34 Average Weekly Movement n/a Healthcare Industry Average Movement 7.1% Market Average Movement 5.6% 10% most volatile stocks in BR Market 10.0% 10% least volatile stocks in BR Market 3.2%
Stabiele aandelenkoers: De aandelenkoers van L1CA34 is de afgelopen 3 maanden volatiel geweest in vergelijking met de BR markt.
Volatiliteit in de loop van de tijd: Onvoldoende gegevens om de volatiliteitsverandering van L1CA34 in het afgelopen jaar te bepalen.
Over het bedrijf Labcorp Holdings Inc. levert laboratoriumdiensten. Het is actief via twee segmenten, Diagnostics Laboratories en Biopharma Laboratory Services. Het bedrijf biedt verschillende tests aan, zoals bloedchemische analyses, urineanalyses, bloedceltellingen, schildklier, PAP, hemoglobine A1C en vitamine D, prostaat-specifieke antigenen, seksueel overdraagbare aandoeningen, hepatitis C, microbiologische kweken en procedures, en alcohol- en ander middelenmisbruiktesten.
Meer tonen Labcorp Holdings Inc. Samenvatting Hoe verhouden de winst en inkomsten van Labcorp Holdings zich tot de beurswaarde? L1CA34 fundamentele statistieken Marktkapitalisatie R$119.38b Inkomsten(TTM ) R$2.51b Inkomsten(TTM ) R$73.21b
47.4x Koers/Winstverhouding Inkomsten en omzet Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM) L1CA34 resultatenrekening (TTM ) Inkomsten US$12.71b Kosten van inkomsten US$9.16b Brutowinst US$3.55b Overige uitgaven US$3.11b Inkomsten US$435.50m
Laatst gerapporteerde inkomsten
Sep 30, 2024
Volgende inkomensdatum
Feb 06, 2025
Winst per aandeel (EPS) 5.21 Brutomarge 27.92% Nettowinstmarge 3.43% Schuld/Eigen Vermogen Verhouding 83.2%
Hoe presteerde L1CA34 op de lange termijn?
Bekijk historische prestaties en vergelijking Dividenden
1.2% Huidig dividendrendement Wanneer moet je L1CA34 kopen om een aanstaand dividend te ontvangen? Labcorp Holdings dividenddata Ex Dividend Datum Feb 26 2025 Betaaldatum dividend Mar 18 2025 Dagen tot Ex-dividend 21 days Dagen tot dividendbetaaldatum 41 days
Bedrijfsanalyse en status van financiële gegevens Gegevens Laatst bijgewerkt (UTC-tijd) Bedrijfsanalyse 2025/02/04 23:59 Aandelenkoers aan het einde van de dag 2025/02/04 00:00 Inkomsten 2024/09/30 Jaarlijkse inkomsten 2023/12/31
Gegevensbronnen De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC . De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
Pakket Gegevens Tijdframe Voorbeeld Amerikaanse bron * Financiële gegevens bedrijf 10 jaar Resultatenrekening Kasstroomoverzicht Balans Consensus schattingen analisten +3 jaar Financiële prognoses Koersdoelen analisten Marktprijzen 30 jaar Aandelenprijzen Dividenden, splitsingen en acties Eigendom 10 jaar Top aandeelhouders Handel met voorkennis Beheer 10 jaar Leiderschapsteam Raad van bestuur Belangrijkste ontwikkelingen 10 jaar
* voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige regelgevingsformulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Lees hier meer.
Analysemodel en Snowflake Details van het analysemodel dat is gebruikt om dit rapport te genereren, zijn beschikbaar op onze Github-pagina . We hebben ook handleidingen voor het gebruik van onze rapporten en tutorials op Youtube .
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op .
Bronnen van analisten Labcorp Holdings Inc. wordt gevolgd door 49 analisten. 17 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
Analist Instelling Jasper Hellweg Argus Research Company Brian Kemp Dolliver Avondale Partners Eric Coldwell Baird
Toon 46 meer analisten 
